GLP-1受体激动剂超说明书用药情况调查及合理性分析

苏芬丽; 沈创鹏; 麦美琪; 利亭婷; 孙旭; 蔡庆群

引用本文:	苏芬丽,沈创鹏,麦美琪,利亭婷,孙旭,蔡庆群.GLP-1受体激动剂超说明书用药情况调查及合理性分析[J].中国现代应用药学,2017,34(11):1611-1615.
	SU Fenli,SHEN Chuangpeng,MAI Meiqi,LI Tingting,SUN Xu,CAI Qingqun.Investigation and Rationally Analysis of Off-label Drug Use of GLP-1 Receptor Agonist[J].Chin J Mod Appl Pharm(中国现代应用药学),2017,34(11):1611-1615.

【打印本页】【HTML】【下载PDF全文】【查看/发表评论】【EndNote】【RefMan】【BibTex】

←前一篇|后一篇→

过刊浏览高级检索

本文已被：浏览 1885次下载 1914次	码上扫一扫！
分享到：微信更多字体:加大+\|默认\|缩小-
GLP-1受体激动剂超说明书用药情况调查及合理性分析
苏芬丽¹, 沈创鹏², 麦美琪^2,3, 利亭婷¹, 孙旭¹, 蔡庆群¹
1.广州中医药大学第一附属医院, 药学部, 广州 510405;2.广州中医药大学第一附属医院, 内分泌科, 广州 510405;3.中山市中医院内分泌科, 广东中山 528400

摘要:

目的了解GLP-1受体激动剂超说明书用药情况，促进临床合理用药。方法采用回顾性调查法，抽取内分泌科2015年12月3日-2016年12月14日使用过GLP-1受体激动剂进行治疗的住院病例，按照药品说明书，判断其超说明书用药情况，对超说明书用药进行分类和统计，并评价其合理性。结果共调查内分泌科住院患者51例，有97例次存在超说明书用药情况，其中超适应证47例次（48.45%），主要表现在联合用药方面，另有50例次（51.55%）属于用法用量超说明书。结论 GLP-1受体激动剂在临床超说明书使用的现象较普遍，某些有其合理性和必要性，但也有不合理用药情况，临床需引起高度重视。

关键词: GLP-1受体激动剂超说明书用药合理用药

DOI：10.13748/j.cnki.issn1007-7693.2017.11.025

分类号:

基金项目:

Investigation and Rationally Analysis of Off-label Drug Use of GLP-1 Receptor Agonist

SU Fenli¹, SHEN Chuangpeng², MAI Meiqi^2,3, LI Tingting¹, SUN Xu¹, CAI Qingqun¹

1.First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Pharmacy of Department, Guangzhou 510405, China;2.First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Endocrine Department, Guangzhou 510405, China;3.Endocrine Department, Hospital of Traditional Chinese Medicine of Zhongshan, Zhongshan 528400, China

Abstract:

OBJECTIVE To investigate the situation of off-label drug use of GLP-1 receptor agonist, so as to promote rational clinical drug use. METHODS By a retrospective survey method, all inpatients in Endocrine Department used GLP-1 receptor agonist from December 3, 2015 to December 14, 2016 were selected, and the situation of off-label drug use was analyzed. RESULTS A total of 51 cases were analyzed, 97 had off-label drug use. The main type of off-label drug use were 47(48.45%) in indications, especially in drug combination, and 50(51.55%) in dose. CONCLUSION The off-label drug use of GLP-1 receptor agonist was common in clinical, and some were reasonable and necessary; yet there were still some irrational phenomenon, which need the close attention by the clinic.

Key words: GLP-1 receptor agonist off-label drug use rational drug use